Action Potential Venture Capital

Action Potential Venture Capital (APVC) is a leading medical technology venture capital firm founded by GSK in 2013. APVC is focused on the next generation of peripheral neuromodulation medical devices, and invests in companies around the world and technologies that enable the future of targeted and adaptive bioelectronics. We believe in the fundamental advantage of an inclusive and diverse workspace and are committed to creating a more equitable healthcare investor and entrepreneurial community. Our commitment begins at APVC through the diversity of the investment team, and we extend this accountability to the companies we invest in. Bioelectronic medicine is an emerging therapeutic field which leverages advances in hardware, computing and material science to regulate neural or cellular activity, and more effectively treat a range of chronic diseases.